

23 October 2018

ASX Announcement

Penthrox approved in Hong Kong

Medical Developments International Limited (ASX: MVP), is pleased to announce that Penthrox® has been granted registration approval in Hong Kong. The registration issued by the Hong Kong Pharmacy and Poisons Board (PPB), is for Penthrox® to be used for:

1. the emergency relief of pain by self-administration in conscious haemodynamically stable patients with trauma and associated pain, under supervision of personnel trained in its use; and
2. the relief of pain in monitored conscious patients who require analgesia for surgical procedures.

Mr John Sharman, Chief Executive Officer said: "Hong Kong is an important market in Asia and we believe this approval will have a positive influence within the region and on achieving Penthrox's approval in China.

Mr Sharman said: "Importantly the approval is for both trauma pain and surgical procedures, and includes the use of Penthrox for children. We have a partner in place in Hong Kong, a subsidiary of Clinigen Group Plc, and we expect sales to commence during FY19."

The Chairman of MVP, Mr David Williams said: "We view the registration as complementary to the Distribution Agreement we have just signed with Daiichi Sankyo for the Chinese market."

Enquiries:

David Williams
Chairman
Medical Developments International Ltd
+61 (0) 414 383 593

John Sharman
Chief Executive Officer
Medical Developments International Ltd
+61 (3) 9547 1888

About Pentrox®

PENTHROX® (methoxyflurane) is the only small, lightweight, handheld, fast-acting, inhaled analgesic that is self-administered under the supervision of the treating healthcare practitioner, indicated for the short-term relief of moderate to severe pain, associated with trauma or interventional medical procedures, in conscious adult patients. Pentrox® provides rapid, effective pain relief in 5 minutes, with no need for needles and is not classified as an opioid. Pentrox® allows patients to control their own pain relief by moderating the amount of Pentrox® inhaled¹.

About Medical Developments International Ltd

MDI is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MDI is a leader in emergency pain relief and respiratory products. The Company manufactures Pentrox®, a fast-acting trauma & pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defense Forces, sports medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MDI is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

About Clinigen Group

Clinigen Group is a UK global pharmaceutical and services company listed on the London Stock Exchange. Clinigen has more than 800 staff across 13 locations, revenue of AUD\$700 million and a market capitalisation of AUD\$2 billion. Clinigen's global footprint extends to supplying 108 countries worldwide and their regulatory expertise and local market knowledge can address patient access needs anywhere in the world. Clinigen's mission is to deliver the right medicine to the right patient at the right time operating in three areas of global medicine supply: clinical trials, unlicensed and licensed medicines.